Partnership for Alzheimer's Research
AmBARI Healthcare, Inc., in collaboration with the Phoenix VA Health Care System and the Arizona Veterans Research and Education Foundation, has initiated a proactive research agreement aimed at better understanding Alzheimer's disease. This significant cooperative agreement will enable the launch of a clinical pilot study that will evaluate innovative treatment approaches for veterans grappling with cognitive impairments.
The study focuses specifically on therapeutic plasma exchange (TPE), a cutting-edge method designed to address early cognitive disorders and mild Alzheimer's symptoms.
Dr. Mitchell Harman, the principal investigator at the Phoenix VA Health Care System, will lead this forward-thinking research. The trial aims to recruit up to
56 veterans, all of whom will undergo comprehensive evaluations utilizing advanced brain imaging techniques, particularly positron emission tomography (PET), alongside the innovative biomarker NAV-4694, which helps measure amyloid plaque levels in the brain.
Research Background
The impetus for this study stems from previous successes in TPE, such as the AMBAR trial conducted by Grifols, which reported promising results in delaying the progression of Alzheimer's disease. The AMBAR trial, which observed nearly
500 patients, found that TPE could potentially delay disease progression by
61% and enhance memory in
11% to 15% of early-stage patients. These findings are bolstered by practical applications witnessed at the Alzheimer Center in Barcelona, where over
2,100 plasma exchange procedures have already been performed, showing the efficacy of TPE in clinical practice.
The Role of Young Blood Institute
The Young Blood Institute has been at the forefront of developing biomarker technology and preclinical studies that reveal the potential for therapeutic plasma exchange to clear harmful beta-amyloid peptides from the bodies of patients without cognitive impairment. The collaboration aims to elevate the study protocol and integrate state-of-the-art imaging technologies, setting a robust framework to investigate the relationship between serum albumin and amyloid peptides.
Implementation and Goals
This landmark study is not just an academic pursuit; it's also a direct response to the urgent need for modern treatments for veterans suffering from Alzheimer's disease. As
Elijah J. Ditter, director of the Phoenix VA Healthcare System, emphasized, this research represents a transformative step in offering veterans access to the latest advancements in translational research, which could lead to significant improvements in their healthcare experiences.
Additionally,
Dr. Samuel M. Aguayo highlighted the system’s commitment to translating research outcomes into practical applications, ensuring that veterans receive the best possible care. This cooperative research agreement seeks to engage veterans in a controlled environment, yielding results that can not only benefit them but could also influence broader clinical practices.
Support from Key Partners
Key partnerships with institutions like the Young Blood Institute empower the Phoenix VA Health Care System and its affiliates to implement innovative treatment methodologies. As emphasized by
Jeremy Greene, managing director of the Arizona Veterans Research and Education Foundation, this collaboration enhances resources available for conducting advanced biomedical research, thus promoting veteran care.
Looking Forward
In conclusion, this joint initiative signifies an enormous stride in Alzheimer’s research, aiming to validate the efficacy of TPE while addressing the pressing needs of the veteran population. With oversight from an independent ethics committee and strict adherence to federal guidelines, the study is set to set precedents in veteran healthcare innovation.
As the partners embark on this research journey, they remain committed to ensuring that veterans have access to effective, evidence-based treatments inspired by cutting-edge science.
For further information, please visit
Phoenix VA Health Care System and
Young Blood Institute.